Clinical implications of an accurate problem list on heart failure treatment

CONTEXT: The premise of the problem-oriented medical record is that an accurately defined problem list will directly result in more thorough and efficient patient care. However, little empirical evidence exists demonstrating improved patient outcomes as a result of an adequately structured problem list.OBJECTIVE: To determine the impact of problem list documentation of heart failure on the likelihood that evidence-based pharmacotherapy has been prescribed.DESIGN: Cross-sectional study.SETTING: Community-based primary care clinics in Portland, Oregon.SUBJECTS: Active patients in the network with a left ventricular ejection fraction of 40% or less, with and without heart failure, in their structured problem list.MAIN OUTCOME MEASURES: The proportion of patients prescribed medications with known benefits for systolic dysfunction.RESULTS: In this group of patients with known systolic dysfunction, the likelihood of therapy with either an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker was higher in patients who had heart failure listed on their problem list compared to patients who did not (92.2% vs 76.7%; P<.05). This association remained after statistical adjustment for age, gender, and ejection fraction. Patients with accurate problem list entries were also more likely to receive digoxin (61.1% vs 36.7%; P=.001) and spironolactone (26.7% vs 13.3% P=.025). There were no differences in the use of beta-blockers between the 2 groups.CONCLUSION: Accurate documentation of heart failure on the problem list of patients with known systolic dysfunction is associated with a significant increase in the likelihood of being prescribed medications with known clinical benefit.

[1]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[2]  S. W. Holman A challenge. , 1955, Medical technicians bulletin.

[3]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[4]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[5]  J. Buring,et al.  Epidemiology in Medicine , 1987 .

[6]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[7]  D W Simborg,et al.  Information Factors Affecting Problem Follow-Up in Ambulatory Care , 1976, Medical care.

[8]  I. Alhaddad,et al.  A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. , 2001, Journal of the American College of Cardiology.

[9]  P. Armstrong,et al.  Insights into the contemporary epidemiology and outpatient management of congestive heart failure. , 1999, American heart journal.

[10]  M. Moser Detection, evaluation, and treatment of high blood pressure. , 1977, New York state journal of medicine.

[11]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[12]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[13]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[14]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[15]  A. Gittelsohn,et al.  Small Area Variations in Health Care Delivery , 1973, Science.

[16]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[17]  L. Weed Medical records that guide and teach. , 1968, The New England journal of medicine.

[18]  Rourke Aj Evaluating the quality of medical care. , 1957, Hospital progress.

[19]  M. Chassin Is health care ready for Six Sigma quality? , 1998, The Milbank quarterly.